ENTITY

Argenx SE (ARGX US)

44
Analysis
Health CareNetherlands
argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.
more
bullishDSM-Firmenich
30 Jul 2024 16:09

Quiddity Leaderboard ES50 Sep 24: Billion Dollar Flows Now in the Money

There could be 23 days of volume to buy in DSM-Firmenich and 15 days of volume to sell in Nokia as things stand. However, this is a low-conviction...

Share
bearishDeutsche Post
25 Jul 2024 22:59

STOXX 50: First September Forecasts for Europe and Eurozone

​In SX5E, Nokia might be replaced by DSM-Firmenich, while in SX5P Reckitt Benckiser and Deutsche Post may be replaced by Intesa Sanpaolo and Banco...

Logo
233 Views
Share
26 Dec 2023 17:07

[Blue Lotus Daily]: ATAT/600754 CH/1211 HK/LI/XPEV/NIO/ZLAB/ARGX/9995 HK/3692 HK

Jinjiang's Oct-Nov RevPAR recovered to 105% of 2019, outperforming industry average. Huawei Harmony Alliance to establish independent stores....

Share
09 Mar 2023 16:41

Hanall Biopharma (009420 KS): Lead Pipeline Asset Moved a Step Closer to Commercialization in China

Hanall’s partner has reported positive top-line results from Phase 3 trial of batoclimab in myasthenia gravis in China. The partner plans to file...

Logo
410 Views
Share
03 Oct 2022 14:58

Hanall Biopharma (009420 KS): Clinical Trial Progress of Key Pipeline Assets to Provide Some Upside

Hanall’s leading pipeline assets are progressing in late-stage trials through licensed global partners, thereby generating milestone payment...

Logo
200 Views
Share
x